Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.51 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973643 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL22654084 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL2804085 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL11220049 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL21585495 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL22654085 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL14965068 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL2214344 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL7780483 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI | |
| SCHEMBL2214348 | 1.00 | TYR (0.55) | TYRTSHRALDH1A1LMNAALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182510-A1 | Compounds Useful in HIV Treatment | VIIV HEALTHCARE COMPANY (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2024062180-A1 | BIOSOURCED ORGANOGELATORS AND ORGANOGELS CONTAINING SAME | SORBONNE UNIVERSITE (FR) | 2024-03-28 | — | — | WO | disclosed |
| EP-4298105-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV Healthcare Company (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230151049-A1 | Compounds Useful in HIV Therapy | VIIV HEALTHCARE COMPANY (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2022182604-A1 | COMPOUNDS USEFUL IN HIV TREATMENT | VIIV HEALTHCARE COMPANY (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151049-A1 | Compounds Useful in HIV Therapy | CCR5, CD4, NPC1 | TYR 2713/4885TSHR 4863/4885ALDH1A1 359/4885 |
| US-20240182510-A1 | Compounds Useful in HIV Treatment | CCR5, G6PD, NPC1 | TYR 2876/4885TSHR 4867/4885ALDH1A1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.